Crossover studies are a better format for comparing equivalent treatments than parallel-group studies

Pharmacy World and Science

Volumn 20, Issue 3, 1998, Pages 113-117

  Cleophas, Ton J M ^a   De Vogel, Ed M ^a  

^a Merwede Ziekenhuis   (Netherlands)

Author keywords

Correlation levels between treatment responses; Crossoverstudies; Equivalent treatments; Parallel group studies

Indexed keywords

DIURETIC AGENT; ENZYME INHIBITOR; FLUOXETINE; GLYCERYL TRINITRATE; ORCIPRENALINE; PHENOXYBENZAMINE;

ANGINA PECTORIS; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PHARMACOLOGY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG RESEARCH; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; MATHEMATICAL MODEL; MEDICAL RESEARCH; PARALLEL DESIGN; QUALITY CONTROL; STATISTICAL ANALYSIS;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-AGONISTS; ANALYSIS OF VARIANCE; CONTROLLED CLINICAL TRIALS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HUMANS; RETROSPECTIVE STUDIES;

EID: 0031900234     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008626002664     Document Type: Article

References (19)

1. Cleophas TJM. Clinical trials: specific problems associated with the use of a placebo-control group. J Mol Med 1995; 73:421-24.
2. Senn SJ. Problems with two stage analysis of crossover trials. Br J Clin Pharmacol 1991;32:133.
3. Senn SJ. Crossover trials in clinical research. Chichester, England: John Wiley & Sons Ltd, 1993.
4. Nies AS, Spielberg SP. Individualization of drug therapy. In: Hardman JL, Limbird LE, eds. Goodman and Gilman's Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 1996: 43-63.
5. Fleiss JL. A critique of recent research on the two-treatment crossover design. Control Clin Trials 1989;10:237-43.
6. Freeman PR. The performance of the two-stage analysis of two-period, two-treatment crossover trials. Stat Med 1989;8: 1421-32.
7. Cleophas TJM. Relevance of correlation between treatment responses. Eur J Clin Pharmacol 1996;50:1-6.
8. Grieve AP. Bayesian analysis of two-treatment crossover studies. Stat Meth Med Res 1994;3:407-29.
9. Cleophas TJM, Fennis JFM, van 't Laar A. Alpha- and beta-blockade and beta-stimulation in Raynaud's syndrome. Angiology 1985;36:219-26.
10. Cleophas TJM. Crossover trials are only useful when there is a positive correlation between the response to different treatment modalities. Br J Clin Pharmacol 1996;41: 235-9.
11. Jackson PR, Yeo WW, Cleophas TJM. Letters to the editor. Br J Clin Pharmacol 1996;42:399-404.
12. Willan AR, Pater JL. Carryover and the two-period crossover clinical trial. Biometrics 1986;42:593-99.
13. Scheffe H. Mixed models. In: Scheffe H, ed. The analysis of variance. New York: John Wiley & Sons, 1959, 261-91.
14. Gram LF. Fluoxetine. N Engl J Med 1994; 331:1354-61.
15. Cardiology Dialogue. Edited by Rapid Literature Service. Cologne, Germany: Limbach GMBH, 1993.
16. Cleophas TJM, Tavenier P. Fundamental issues of choosing the right type of trial. Am J Ther 1994;1:327-32.
17. Lee ML, Lusher JM. The problem of therapeutic equivalence with paired qualitative data: an example from a clinical trial using haemophiliacs with an inhibitor to factor VIII. Stat Med 1991;10:433-41.
18. Blackwelder WC. Proving the null hypothesis in clinical trials. Control Clin Trials 1982;3:345-53.
19. Cleophas TJM, van Lier HJ. Crossover studies with a binary response: a powerful method in spite of crossover effect. J Clin Pharmacol 1996;36:198-204.